Results 61 to 70 of about 869,771 (326)

Determination of ADP/ATP translocase isoform ratios in malignancy and cellular senescence

Molecular Oncology, EarlyView.
The individual functions of three isoforms exchanging ADP and ATP (ADP/ATP translocases; ANTs) on the mitochondrial membrane remain unclear. We developed a method for quantitatively differentiating highly similar human ANT1, ANT2, and ANT3 using parallel reaction monitoring. This method allowed us to assess changes in translocase levels during cellular
Zuzana Liblova, Dominika Maurencova, Barbora Salovska, Marek Kratky, Tomas Mracek, Zuzana Korandova, Alena Pecinova, Pavla Vasicova, David Rysanek, Ladislav Andera, Ivo Fabrik, Rudolf Kupcik, Pavel Kashmel, Pinky Sultana, Vojtech Tambor, Jiri Bartek, Josef Novak, Marie Vajrychova, Zdenek Hodny   +18 more
wiley   +1 more source

XXIX Italian Melanoma Intergroup National Congress | 29 September - 1 October 2023, Naples (Italy)

Dermatology Reports
s from the Italian Melanoma Intergroup (IMI) XXIX National ...
Italian Melanoma Intergroup (IMI)
doaj   +1 more source

Malignant melanoma of the urethra: a rare histologic subdivision of vulvar cancer with a poor prognosis [PDF]

, 2012
Malignant melanoma of the urethra is a rare tumour that is difficult to diagnose and treat, resulting in a poor prognosis. In this paper, we present the case of a 65-year-old woman who was referred to a gynaecologist because of a urethral mass that ...
Alkatout, Ibrahim, Altarac, Silvio, Cupic, Hrvoje, Fures, Rajko, Günther, Veronika, Hrgovic, Zlatko, Lez, Cvjetko, Mundhenke, Christoph, Persec, Zoran   +8 more
core   +2 more sources

Early metastasis is characterized by Gr1+ cell dysregulation and is inhibited by immunomodulatory nanoparticles

Molecular Oncology, EarlyView.
Breast cancer metastasis is associated with myeloid cell dysregulation and the lung‐specific accumulation of tumor‐supportive Gr1+ cells. Gr1+ cells support metastasis, in part, through a CHI3L1‐mediated mechanism, which can be targeted and inhibited with cargo‐free, polymeric nanoparticles.
Jeffrey A. Ma, Sophia M. Orbach, Kate V. Griffin, Kathryn Kang, Yining Zhang, Rebecca S. Pereles, Ian A. Schrack, Guillermo Escalona, Jacqueline S. Jeruss, Lonnie D. Shea   +9 more
wiley   +1 more source

Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy

Journal of Immunology Research, 2015
Malignant melanoma is a devastating disease whose incidences are continuously rising. The recently approved antimelanoma therapies carry new hope for metastatic patients for the first time in decades.
R. Ortenberg, S. Sapoznik, D. Zippel, R. Shapira-Frommer, O. Itzhaki, A. Kubi, D. Zikich, M. J. Besser, J. Schachter, G. Markel   +9 more
doaj   +1 more source

Osteopontin and `Melanoma Inhibitory Activity': Comparison of Two Serological Tumor Markers in Metastatic Uveal Melanoma Patients [PDF]

, 2009
Background: Evaluation of the protein osteopontin (OPN) as a potential new marker in comparison to melanoma inhibitory activity (MIA) for screening and detection of metastatic uveal melanoma. Methods: Plasma levels of 32 patients with uveal melanoma were
Haritoglou, Christos, Haritoglou, Ingrid, Hein, Ruediger, Maier, Tanja, Schaller, Ulrich Christoph, Wolf, Armin   +5 more
core   +1 more source

Landscape of BRAF transcript variants in human cancer

Molecular Oncology, EarlyView.
We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda, Danilo Tatoni, Gianluca Mattei, Alberto Magi, Romina D'Aurizio, Laura Poliseno   +5 more
wiley   +1 more source

Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma

OncoImmunology, 2017
The optimal sequencing of targeted treatment and immunotherapy in the treatment of advanced melanoma is a key question and prospective studies to address this are ongoing. Previous observations suggest that treating first with targeted therapy may select
Ester Simeone, Antonio Maria Grimaldi, Lucia Festino, Diana Giannarelli, Vito Vanella, Marco Palla, Marcello Curvietto, Assunta Esposito, Giuseppe Palmieri, Nicola Mozzillo, Paolo Antonio Ascierto   +10 more
doaj   +1 more source

Radiation therapy for melanoma brain metastases: a systematic review

Radiology and Oncology, 2022
Radiation therapy (RT) for melanoma brain metastases, delivered either as whole brain radiation therapy (WBRT) or as stereotactic radiosurgery (SRS), is an established component of treatment for this condition.
Thompson John F., Williams Gabrielle J., Hong Angela M.   +2 more
doaj   +1 more source

BRAFV600E mutation positive metastatic melanoma in a young woman treated with anti-BRAF/anti MEK combination: a case report [PDF]

, 2015
The recent Combi-v [1] and Combi-d [2,3], phase III randomized trials, showed, respectively, an OS benefit with Dabrafenib/Trametinib combination versus Vemurafenib and an improvement in PFS and ORR with the same combination versus Dabrafenib alone ...
CORTESI, Enrico, GIOVANNONI, SARA, Giuliana, Caprio, MEZI, Silvia, MODICA, DANIELA, URBANO, FEDERICA, VERKHOVSKAIA, SOFIA   +6 more
core   +2 more sources